Corrected Disclosures Statement | Oncology | JAMA Oncology | JAMA Network
[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 325
Citations 0
August 1, 2019

Corrected Disclosures Statement

JAMA Oncol. 2019;5(9):1372. doi:10.1001/jamaoncol.2019.3356

In the Research Letter titled “Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia,”1 published online first May 17, 2018, and in print July 12, 2018, the Funding/Support statement should have been a Conflict of Interest Disclosures statement and should have included the following omitted disclosure: “Dr Hu reported receiving funding from The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.” This article was corrected online.

Accordino  MK, Wright  JD, Vasan  S,  et al.  Assessment of electronic alert to reduce overuse of granulocyte colony-stimulating factor in patients hospitalized for febrile neutropenia.  JAMA Oncol. 2018;4(7):996-998. doi:10.1001/jamaoncol.2018.0818PubMedGoogle ScholarCrossref